Standard Biotools Stock Current Valuation
| LAB Stock | USD 1.21 0.05 4.31% |
Valuation analysis of Standard Biotools helps investors to measure Standard Biotools' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of March 22, 2025, Enterprise Value Over EBITDA is expected to decline to -4.31. In addition to that, Enterprise Value Multiple is expected to decline to -4.31. Fundamental drivers impacting Standard Biotools' valuation include:
Undervalued
Today
Please note that Standard Biotools' price fluctuation is dangerous at this time. Calculation of the real value of Standard Biotools is based on 3 months time horizon. Increasing Standard Biotools' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Standard Biotools is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Standard Stock. However, Standard Biotools' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.21 | Real 1.66 | Target 3.08 | Hype 1.18 | Naive 1.2 |
The real value of Standard Stock, also known as its intrinsic value, is the underlying worth of Standard Biotools Company, which is reflected in its stock price. It is based on Standard Biotools' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Standard Biotools' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Standard Biotools helps investors to forecast how Standard stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Standard Biotools more accurately as focusing exclusively on Standard Biotools' fundamentals will not take into account other important factors: Standard Biotools Company Current Valuation Analysis
Standard Biotools' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Standard Biotools Current Valuation | 187.33 M |
Most of Standard Biotools' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Standard Biotools is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Standard Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Standard Biotools is extremely important. It helps to project a fair market value of Standard Stock properly, considering its historical fundamentals such as Current Valuation. Since Standard Biotools' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Standard Biotools' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Standard Biotools' interrelated accounts and indicators.
Click cells to compare fundamentals
Standard Current Valuation Historical Pattern
Today, most investors in Standard Biotools Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Standard Biotools' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Standard Biotools current valuation as a starting point in their analysis.
Standard Biotools Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Standard Biotools has a Current Valuation of 187.33 M. This is 98.7% lower than that of the Life Sciences Tools & Services sector and 97.6% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.87% higher than that of the company.
Standard Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Standard Biotools' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Standard Biotools could also be used in its relative valuation, which is a method of valuing Standard Biotools by comparing valuation metrics of similar companies.Standard Biotools is currently under evaluation in current valuation category among its peers.
Standard Fundamentals
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 187.33 M | ||||
| Shares Outstanding | 378.99 M | ||||
| Shares Owned By Insiders | 1.85 % | ||||
| Shares Owned By Institutions | 73.10 % | ||||
| Number Of Shares Shorted | 13.5 M | ||||
| Price To Earning | (2.52) X | ||||
| Price To Book | 0.95 X | ||||
| Price To Sales | 2.52 X | ||||
| Revenue | 174.43 M | ||||
| Gross Profit | 84.26 M | ||||
| EBITDA | (118.14 M) | ||||
| Net Income | (138.88 M) | ||||
| Cash And Equivalents | 81.31 M | ||||
| Cash Per Share | 2.68 X | ||||
| Total Debt | 33 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 5.87 X | ||||
| Book Value Per Share | 1.23 X | ||||
| Cash Flow From Operations | (143.45 M) | ||||
| Short Ratio | 6.28 X | ||||
| Earnings Per Share | (0.52) X | ||||
| Price To Earnings To Growth | 0.31 X | ||||
| Target Price | 2.38 | ||||
| Number Of Employees | 814 | ||||
| Beta | 1.62 | ||||
| Market Capitalization | 439.62 M | ||||
| Total Asset | 612.34 M | ||||
| Retained Earnings | (1.19 B) | ||||
| Working Capital | 309.99 M | ||||
| Net Asset | 612.34 M |
About Standard Biotools Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Standard Biotools's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Standard Biotools using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Standard Biotools based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:Check out Standard Biotools Piotroski F Score and Standard Biotools Altman Z Score analysis. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets | Return On Equity |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.